Oseltamivir Phosphate NDC 64380-879

NDC codes

FDA NDC Directory

Product NDC (as listed)64380-879Labeler and product segments. Claims need a package NDC.

Product NDC at billing width64380-0879Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
64380-879-75	64380087975	1 BOTTLE, GLASS in 1 CARTON (64380-879-75) / 60 mL in 1 BOTTLE, GLASSMarketed from Oct 24, 2022

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Oseltamivir Phosphate
Generic name (nonproprietary): oseltamivir phosphate
Active ingredients: Oseltamivir phosphate — 6 mg/mL
Dosage form: Powder, For suspension
Route: Oral
Labeler: Strides Pharma Science Limited
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 211894
Marketing start: Oct 24, 2022
Listing expires: Dec 31, 2027
Other FDA classes: Neuraminidase Inhibitors (Mechanism)
Identifiers: Product ID 64380-879_e06bd11c-1168-4f2a-b6b3-d6bca21707e8SPL ID e06bd11c-1168-4f2a-b6b3-d6bca21707e8SPL set ID 39255500-0ffd-4d72-abe8-257570b543e7RxCUI 1115698UNII 4A3O49NGEZUPC 0364380879756
Pharmacologic class: Neuraminidase Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N464380087975 followed by a unit qualifier and the quantity

Package 64380-0879-75. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Sep 9, 2025.

Indications (excerpt from the label)

Oseltamivir phosphate for oral suspension is an influenza neuraminidase inhibitor (NAI) indicated for: Treatment of acute, uncomplicated influenza A and B in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours. (1.1) Prophylaxis of influenza A and B in patients 1 year and older. (1.2) Limitations of Use: Not a substitute for annual influenza vaccination. (1.3) Consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use. (1.3) Not recommended for patients with end-stage renal disease not undergoing dialysis. (1.3) 1.1 Treatment of Influenza Oseltamivir phosphate for oral suspension is indicated f…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)